We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-10.24%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$3.03B
AUM Growth
-$37.2M
Cap. Flow
+$370M
Cap. Flow %
12.2%
Top 10 Hldgs %
57.55%
Holding
43
New
5
Increased
14
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$102M
2
MDT icon
Medtronic
MDT
+$75.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$45.2M
4
GMED icon
Globus Medical
GMED
+$40.5M
5
THC icon
Tenet Healthcare
THC
+$33.6M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$66.6M
2
WBA
Walgreens Boots Alliance
WBA
+$61.2M
3
QTRX icon
Quanterix
QTRX
+$53.2M
4
GSK icon
GSK
GSK
+$44.4M
5
CNC icon
Centene
CNC
+$27M

Sector Composition

Rank Sector Weight
1 Healthcare 88.25%
2 Consumer Staples 2.31%
3 Consumer Discretionary 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UHS icon
1
Universal Health Services
UHS
$10.2B
$251M 8.29%
2,000,000
+75,000
+4% +$10.2M
PFE icon
2
CALL
Pfizer
PFE
$143B
$249M 8.2%
+7,500,000
New +$265M
THC icon
3
Tenet Healthcare
THC
$22.2B
$240M 7.93%
3,650,000
+450,000
+14% +$33.6M
ZBH icon
4
Zimmer Biomet
ZBH
$18.8B
$208M 6.84%
1,850,000
+800,000
+76% +$102M
VTRS icon
5
Viatris
VTRS
$20.8B
$197M 6.5%
20,000,000
-2,500,000
-11% -$26M
SNY icon
6
Sanofi
SNY
$107B
$148M 4.86%
2,750,000
-1,250,000
-31% -$66.6M
MDT icon
7
Medtronic
MDT
$112B
$118M 3.87%
1,500,000
+900,000
+150% +$75.3M
WBA
8
DELISTED
Walgreens Boots Alliance
WBA
$116M 3.81%
5,200,000
-2,300,000
-31% -$61.2M
BAX icon
9
Baxter International
BAX
$12.8B
$113M 3.73%
3,000,000
– –
MYGN icon
10
Myriad Genetics
MYGN
$476M
$106M 3.51%
6,635,000
– –
TEVA icon
11
Teva Pharmaceuticals
TEVA
$40.4B
$104M 3.41%
10,150,000
+1,650,000
+19% +$15.4M
GSK icon
12
GSK
GSK
$107B
$103M 3.41%
2,850,000
-1,250,000
-30% -$44.4M
IONS icon
13
Ionis Pharmaceuticals
IONS
$8.93B
$102M 3.36%
2,250,000
-250,000
-10% -$10.3M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.64B
$97M 3.2%
800,000
+400,000
+100% +$45.2M
SEM
15
DELISTED
Select Medical
SEM
$85.9M 2.83%
6,310,400
-1,206,400
-16% -$18.6M
GMED icon
16
Globus Medical
GMED
$11.1B
$85.6M 2.82%
1,725,000
+725,000
+73% +$40.5M
PTCT icon
17
PTC Therapeutics
PTCT
$6.18B
$76.2M 2.51%
3,400,000
+900,000
+36% +$33.5M
BKD icon
18
Brookdale Senior Living
BKD
$3.55B
$74.5M 2.46%
18,000,000
– –
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$65.3M 2.15%
1,500,000
-300,000
-17% -$10.7M
XRAY icon
20
Dentsply Sirona
XRAY
$2.84B
$60.3M 1.99%
1,765,000
– –
PRGO icon
21
Perrigo
PRGO
$1.44B
$59.1M 1.95%
1,850,000
-650,000
-26% -$22.9M
HLF icon
22
Herbalife
HLF
$1.3B
$39.9M 1.31%
2,850,000
+100,000
+4% +$1.51M
QTRX icon
23
Quanterix
QTRX
$159M
$34.6M 1.14%
1,275,000
-2,150,000
-63% -$53.2M
REPL icon
24
Replimune Group
REPL
$455M
$34.2M 1.13%
2,000,000
+450,000
+29% +$8.84M
ZIMV
25
DELISTED
ZimVie
ZIMV
$30.6M 1.01%
3,250,000
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Camber Capital Management held 43 positions worth $3.03B, down 1.2% from $3.07B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Camber Capital Management deployed $370M of net new capital in Q3 2023, opening 5 new positions and adding to 14 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 300,000 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Sanofi, an estimated $66.6M trimmed.

  • Camber Capital Management's largest Q3 2023 buy was BioMarin Pharmaceuticals: 300,000 shares worth $26.5M.
  • Camber Capital Management added most to Zimmer Biomet in Q3 2023, an estimated $102M increase.
  • Camber Capital Management's biggest Q3 2023 reduction was Sanofi, cutting an estimated $66.6M.
  • Camber Capital Management fully exited Centene in Q3 2023, selling an estimated $27M.
  • Camber Capital Management's ten largest holdings make up 58% of its $3.03B portfolio in Q3 2023.
  • Camber Capital Management opened 5 new positions and closed 3 in Q3 2023.
  • Camber Capital Management's portfolio value fell 1.2% quarter-over-quarter to $3.03B.

Based on Camber Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.